Merck Completes SpringWorks Acquisition to Boost Healthcare Growth
Merck Finalizes $3.4 Billion Acquisition of SpringWorks Therapeutics to Strengthen Rare Tumor Portfolio and Drive Sustainable Healthcare Growth Merck, a global leader in science and technology, today announced the successful…
Vertex’s ALYFTREK® Approved in EU for Cystic Fibrosis Treatment
Vertex Gains EU Approval for ALYFTREK®, a Next-Generation CFTR Modulator for Cystic Fibrosis Patients Vertex Pharmaceuticals (Nasdaq: VRTX) announced today that the European Commission has granted marketing authorization for ALYFTREK®…
Riliprubart Receives Orphan Drug Designation in Japan for CIDP
Riliprubart Receives Orphan Drug Designation in Japan for Chronic Inflammatory Demyelinating Polyneuropathy Sanofi announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to riliprubart,…
Amgen Reports Positive Phase 3 Results for Bemarituzumab in FGFR2b+ Gastric Cancer
Amgen Reports Positive Phase 3 Results for Bemarituzumab in FGFR2b+ Gastric Cancer, Marking Milestone in Targeted Therapy Amgen (NASDAQ:AMGN) has announced a significant breakthrough in the treatment of gastric and…
Strategic Leadership Changes Announced by Roche
Roche Announces Key Leadership Transitions Within Enlarged Corporate Executive Committee Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced significant changes to its leadership team, as two esteemed members of its…
AbbVie to Acquire Capstan to Boost Immunology Innovation
AbbVie to Acquire Capstan Therapeutics to Advance In Vivo CAR-T for Autoimmune Diseases AbbVie and Capstan Therapeutics have announced a definitive agreement for AbbVie to acquire Capstan in a move…
FDA Reviews Allergan’s SKINVIVE PMA for Neck Appearance Improvement
FDA Accepts Allergan’s Application to Expand SKINVIVE by JUVÉDERM® for Neck Line Treatment Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that the U.S. Food and Drug Administration (FDA) has…
Evaluating the Risk of NAION in Patients Using Semaglutide Medications
WHO Issues Global Safety Alert Over Vision Loss Risk Linked to Semaglutide-Based Medications The World Health Organization (WHO) has issued a global safety communication directed at healthcare professionals and regulatory…
WHO Scientific Group Publishes Findings on COVID-19’s Origins
WHO Scientific Advisory Group Releases In-Depth Report on the Origins of COVID-19 Amid Ongoing Calls for Transparency and Global Cooperation The World Health Organization (WHO) has taken another step forward…
WHO and Key Stakeholders Launch Disability Health Equity Partnership
WHO Launches Landmark Global Initiative to Advance Health Equity for Over 1.3 Billion People with Disabilities In a pivotal step toward realizing global health equity, the World Health Organization (WHO)…
UCB’s GEMZ Phase 3 Trial Shows Promising Results for Fenfluramine in Treating CDKL5 Deficiency Disorder
UCB Announces Promising Phase 3 Results for Fenfluramine in CDKL5 Deficiency Disorder, Marking a Major Step Forward in Rare Epilepsy Treatment UCB, a global biopharmaceutical company committed to developing innovative…
European Union Authorizes Eylea 8 mg with Prolonged 6-Month Treatment Schedule
European Commission Grants Approval for Eylea™ 8 mg with Extended 6-Month Dosing Interval in Patients with nAMD and DME The European Commission (EC) has officially approved a label extension for…